One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
Achievable but elusive: LLDAS and DORIS remission in clinical trials of belimumab
Reclassifying ANCA-associated vasculitis: a focus on kidney disease
Treating antineutrophil cytoplasmic antibody-associated vasculitis in frail older adults
Uveitis relapse in Behçet's disease: a more nuanced approach is needed
Challenges and solutions for cellular therapy development in autoimmune diseases
Explanation for substandard of care comparators in rheumatology randomised trial protocols
Inclusive study design to better serve the needs of children and young people with rheumatological conditions
Inclusion of pregnant populations in clinical trials in China: the ethical considerations
Gout in central Asia: a few things make a big difference – Authors' reply
Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials
Data-driven subclassification of ANCA-associated vasculitis: model-based clustering of a federated international cohort
The effects of age and frailty on the risks of end-stage renal disease, death, and severe infection in older adults with antineutrophil cytoplasmic antibody-associated vasculitis: a retrospective cohort study
Combinations of immunomodulatory agents for prevention of uveitis relapse in patients with severe Behçet's disease already on corticosteroid therapy: a randomised, open-label, head-to-head trial
Arthritis complicating inflammatory bowel disease— the future is now
